|
#211
09.09.2009, 11:10
|
||||
|
||||
|
Âîçìîæíî, êòî-òî óæå âûêëàäûâàë:
Immediate vs Delayed Intervention for Acute Coronary Syndrome [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 
|
|
#212
11.09.2009, 09:30
|
||||
|
||||
|
Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. J Am Coll Cardiol 2009;54:1089-1095. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Study Question: Is dronedarone as effective as amiodarone for the suppression of atrial fibrillation (AF)? Late Donor Cardiectomy After Paediatric Heterotopic Cardiac Transplantation Tsang V, Yacoub M, Sridharan S, et al. Lancet 2009;374:387-392. Study Question: Can post-transplant lymphoproliferative disorder (PTLD) be cured by cessation of immunosuppression following the removal of the transplanted organ? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Wallentin L, Becker RC, Budaj A, et al., on behalf of the PLATO Investigators. N Engl J Med 2009;Aug 30:[Epub ahead of print]. Study Question: Is ticagrelor superior to clopidogrel for the prevention of ischemic coronary events following presentation with acute coronary syndrome (ACS)? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel With or Without a Proton-Pump Inhibitor: An Analysis of Two Randomized Trials O'Donoghue ML, Braunwald E, Antman EM, et al. Lancet 2009;Sep 1:[Epub ahead of print]. Study Question: What is the association between proton-pump inhibitor (PPI) use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease: A Randomized Controlled Trial Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. J Am Coll Cardiol 2009;54:505-512. Study Question: Does spironolactone, in addition to any angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARB), improve left ventricular (LV) mass and arterial stiffness in early-stage chronic kidney disease (CKD)? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Reduction in Acute Myocardial Infarction Mortality in the United States: Risk-Standardized Mortality Rates From 1995-2006 Krumholz HM, Wang Y, Chen J, et al. JAMA 2009;302:767-773. Study Question: Has there been a significant change in patient-specific or hospital-specific 30-day risk-standardized mortality rates (RSMRs) for patients discharged with an acute myocardial infarction (AMI) between 1995 and 2006? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Intravascular Ultrasound Results From the ENDEAVOR IV Trial: Randomized Comparison Between Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease Waseda K, Miyazawa A, Ako J, et al., on behalf of the ENDEAVOR IV Trial Investigators. JACC Cardiovasc Interv 2009;2:779-784. Study Question: What is the difference in the vascular response to zotarolimus-eluting stents (ZES) and paclitaxel-eluting stents (PES), as determined by intravascular ultrasound (IVUS)? Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation: A Randomised Non-inferiority Trial Holmes DR, Reddy VY, Turi ZG, et al., on behalf of the PROTECT AF Investigators. Lancet 2009;374:534-542. Study Question: What is the efficacy and safety of percutaneous closure of the left atrial appendage (LAA) for prevention of stroke compared with warfarin treatment in patients with atrial fibrillation? Prediction of Mortality and Major Cardiac Events by Exercise Echocardiography in Patients With Normal Exercise Electrocardiographic Testing Bouzas-Mosquera A, Peteiro J, Alvarez-Garcia N, et al. J Am Coll Cardiol 2009;53:1981-1990. Study Question: What is the prognostic significance of exercise echocardiography (EE) in patients with known or suspected coronary disease and a normal exercise electrocardiogram (ECG)? Home Therapy of Venous Thrombosis With Long-Term LMWH Versus Usual Care: Patient Satisfaction and Post-Thrombotic Syndrome Hull RD, Pineo GF, Brant R, et al., on behalf of the LITE Trial Investigators. Am J Med 2009;122:762-769. Study Question: What is the effect of treatment for deep vein thrombosis (DVT) with long-term low molecular weight heparin (LMWH) versus usual care?
|
|
#213
11.09.2009, 09:35
|
||||
|
||||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#214
11.09.2009, 19:29
|
||||
|
||||
|
Reasons for Delays in Defibrillation
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] IC Streptokinase Limits Infarct Size [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Use of DES vs. BMS [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] New Journal Scans: B-CONVINCED: beta-blockade continuation vs. discontinuation during ADHF (EHJ). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with AF (JACC). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] New Clinical Trials: Long-term outcome of DES compared with BMS in STEMI (PASEO). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Perioperative statin therapy in patients undergoing vascular surgery (DECREASE III). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Call for Abstracts: ACC is now accepting abstracts for ACC.10 & i2.10. The deadline is October 6. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ESC Congress 2009: Cardiosource's complete coverage, including slides and video interviews. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] For a quick look at clinical trial results, download our summary slide compilation! [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#215
12.09.2009, 12:49
|
||||
|
||||
|
Carl J. Lavie, Richard V. Milani, and Hector O. Ventura
Obesity and Cardiovascular Disease: Risk Factor, Paradox, and Impact of Weight Loss J. Am. Coll. Cardiol. 2009;53;1925-1932 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#216
12.09.2009, 14:50
|
||||
|
||||
|
ACC 2009 Survey Results and Recommendations:
Addressing the Cardiology Workforce Crisis [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#219
23.09.2009, 19:20
|
||||
|
||||
|
ACCF/AHA 2009 Performance Measures for Primary
Prevention of Cardiovascular Disease in Adults [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] A Curriculum on Prevention of Cardiovascular Disease [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#220
24.09.2009, 10:34
|
||||
|
||||
|
SPIRIT IV: EES looks superior to PES at 1 year
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] COMPARE: EES reduces cardiovascular events vs PES [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ISAR-DESIRE 2: No difference in type of DES for treating in-stent restenosis [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] SIRTAX-LATE: 5-year results show equal outcomes with PES and SES [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ENDEAVOR IV: ZES stents beat out PES at 3 years [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#221
24.09.2009, 14:39
|
|||
|
|||
|
Öèòàòà:
|
|
#222
25.09.2009, 10:32
|
||||
|
||||
|
New ASCOT Analysis: Beta Blockers Not Beneficial in Hypertensives With Tachycardia
News Author: Lisa Nainggolan September 24, 2009 — A new analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm (ASCOT-BPLA) shows that the amlodipine (Norvasc, Pfizer)-based arm of the study remained superior to the beta-blocker arm, even when resting heart rate was taken into account [1]. The study was published in the September 22, 2009 issue of the Journal of the American College of Cardiology. The findings mean that "there is no reason to believe that beta blockers should be used earlier on in the treatment of hypertension on the basis of heart rate," lead author Dr Neil R Poulter (Imperial College London, UK) told heartwire . He said many cardiologists have had "a hindbrain belief" that "if there is a touch of tachycardia, beta blockers are the right drugs to use in hypertension management." But prior to this analysis, there had been no data from randomized controlled trials available to assess the impact of this advice on patient outcomes, he noted. No Attenuation of Amlodipine Superiority on Basis of Heart Rate The ASCOT trial enrolled 19 257 hypertensive patients with at least three other cardiovascular risk factors from 650 general practices in the UK, Ireland, and the Nordic countries. The results showed that an antihypertensive strategy based on amlodipine, with perindopril added as required, significantly reduced all-cause mortality and other cardiovascular end points, including stroke, compared with an atenolol-based strategy, with the diuretic bendroflumethiazide added as required. In this new subgroup analysis, patients with atrial fibrillation or taking rate-limiting antihypertensive drugs at baseline were excluded. The potential attenuation of the treatment effect with higher baseline heart rate on total cardiovascular events and procedures (TCVP) was assessed via an interaction term. Secondary analyses evaluated coronary and stroke outcomes. There were 12 759 of the ASCOT patients included and 1966 total cardiovascular events and procedures. At the final visit, mean heart-rate reduction from baseline was 12.0 and 1.3 beats per minute in the atenolol- and amlodipine-based groups, respectively. There was a reduction in total cardiovascular events and procedures in those allocated to amlodipine-based therapy compared with those on atenolol-based therapy (unadjusted hazard ratio 0.81; p<0.001). Until further notice, beta blockers should not come up the pecking order on the basis of pulse rate. This benefit was unattenuated at higher heart rates (interaction p value=0.82). Similar results were obtained for coronary and total stroke outcomes. Poulter has served as a consultant to and received travel expenses, payment for speaking at meetings, or funding for research from one or more pharmaceutical companies marketing BP-lowering or lipid-lowering drugs. Poulter has also previously received financial support from Pfizer to cover administrative and staffing costs of the ASCOT study and travel or accommodation expenses or both incurred by attending relevant meetings. Disclosures for the coauthors are listed in the paper. References Poulter NR, Dobson JE, Sever PS, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54:1154-1161. Clinical Context Resting heart rate has been shown to be a significant predictor of all-cause and CV mortality among men and women, including patients with hypertension, and heart rate reduction has been one of the important mechanisms for beta-blockers to exert their beneficial effects. However, it is not certain if superior effects of amlodipine on CV outcomes in patients with hypertension are attenuated by higher resting heart rate and whether beta-blockers should be a first-line treatment in patients with hypertension and a higher baseline heart rate. This is an examination of data from the ASCOT trial, a 2 x 2-factorial design trial comparing CV outcomes in patients with hypertension treated with atenolol vs amlodipine with or without lipid-lowering therapy. Study Highlights ASCOT recruited 19,257 patients between 1998 and 2000 from family practices in the United Kingdom, Ireland, and the Nordic countries and randomly assigned them to atenolol (with or without bendroflumethiazide) or amlodipine (with or without perindopril). Included were patients aged 40 to 79 years with untreated hypertension (systolic BP ≥ 160 mm Hg and diastolic BP ≥ 100 mm Hg) who had at least 3 CV risk factors. The CV risk factors included male sex, age 55 years or older, microalbuminuria or proteinuria, smoking, total to high-density lipoprotein cholesterol ratio of 6 or higher, premature coronary disease in the family, left ventricular hypertrophy, and comorbidities that increase CV risk. Excluded were patients with a previous history of myocardial infarction, current angina, cerebrovascular event within 3 months, fasting triglyceride level of more than 4.5 mmol/L, heart failure, arrhythmias including atrial fibrillation, or beta-blocker at screening. Heart rate and BP were measured at screening, baseline, and at every follow-up visit (6 weeks, 3 months, 6 months, and then every 6 months). Heart rate and BP were measured 3 times at each visit, and the mean of the last 2 readings was used for analysis. Baseline heart rate was analyzed as a continuous variable and also at intervals of 10 beats per minute. The primary outcome was the effect of baseline heart rate on the effect of either atenolol or amlodipine on TCVP. Secondary analyses examined stroke and coronary outcomes. Mean age of the patients was 63 years, one quarter had diabetes, one third were smokers, and one quarter were taking antihypertensive medications at baseline. Mean systolic BP was 165 mm Hg and mean diastolic BP was 95 mm Hg, with a mean baseline heart rate of 74 beats per minute. Baseline heart rates were higher among women, smokers, and diabetic patients. Heart rate decreased with increasing age and increased with increasing body mass index, BP, alcohol intake, triglyceride levels, and glucose levels. There were 12,759 patients with 1966 TCVP. Allocation to atenolol was associated with a decrease in heart rate regardless of baseline heart rate, with a mean heart rate reduction of 12 beats per minute. Allocation to amlodipine was associated with increased heart rate in the lowest tertile of baseline heart rate, no change in the middle tertile, and reduced heart rate in the highest baseline tertile, with an average decrease in heart rate of 1.3 beats per minute overall. Baseline heart rate did not affect TCVP, nonfatal myocardial infarction, or total stroke outcomes. Allocation to amlodipine was associated with significantly better CV outcomes vs allocation to atenolol, and this was not attenuated by higher baseline heart rate in either group. The heart rate for TCVP reduction in the amlodipine group vs the atenolol group was 0.81 (P < .0001). The effect on the 3 CV outcomes was not affected by baseline heart rate in the amlodipine group. The authors concluded that baseline heart rate in patients with hypertension did not attenuate the CV benefits of amlodipine treatment and that this does not support use of beta-blockers in patients with hypertension and a higher baseline heart rate. Clinical Implications Use of atenolol vs amlodipine in patients with hypertension is associated with a greater reduction in heart rate vs baseline heart rate. The CV benefits of amlodipine are not attenuated by baseline heart rate in patients with hypertension.
|
|
#223
25.09.2009, 12:36
|
||||
|
||||
|
Öèòàòà:
|
|
#224
25.09.2009, 18:40
|
||||
|
||||
|
COGENT: No CV harm, but large GI benefit with PPI and clopidogrel
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] CURRENT OASIS 7 SUBSTUDY: High-dose clopidogrel beneficial in STEMI PCI [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] CHARISMA GENOMICS SUBSTUDY: Only 2C19 homozygotes show muted clopidogrel effect [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] TRITON-TIMI 38 ECONOMIC SUBSTUDY: Prasugrel very cost-effective in PCI for ACS; reduced CV hospitalization seen [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] PLATO INVASIVE: Benefit of ticagrelor over clopidogrel in invasive stategy [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#225
26.09.2009, 10:50
|
||||
|
||||
|
SYMPLICITY I: Novel percutaneous technique for hypertension shows promise
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] HORIZONS-AMI: Bivalirudin remains non-inferior in STEMI [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] HORIZONS-AMI Stent: PES beats BMS in STEMI at 2 years [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] BCIS-1: No benefit of routine IABP insertion for high-risk PCI [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] NORDIC-BALTIC BIFURCATION STUDY III: No benefit with kissing balloons [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] FAUST: Ultrasound guidance for femoral access may help [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
Ëèíåéíûé âèä
